

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **JMT202 (RECOMBINANT FULLY HUMAN ANTI- $\beta$ KLOTHO MONOCLONAL ANTIBODY DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that JMT202 (the “**Product**”), a recombinant fully human anti-  $\beta$  Klotho monoclonal antibody drug developed by the Group, has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S. The Product also obtained approval from the National Medical Products Administration of the People’s Republic of China in May 2024 and is currently undergoing clinical trials in China.

The Product is an FGFR1c/  $\beta$  Klotho receptor agonist that specifically activates the FGFR1c/  $\beta$  Klotho receptor complex by binding to  $\beta$  Klotho protein, thereby mimicking the action of its natural ligand, FGF21 protein, to regulate glycolipid metabolism. The Product is potentially useful for the treatment of metabolism-related diseases such as dyslipidemia, metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes, and obesity, and also has the potential to be used in combination with other targeted drugs (such as GLP-1) that regulate glycolipid metabolism. The indication for this clinical trial approval is hypertriglyceridemia (HTG). Preclinical studies demonstrated that with a good safety profile and long dosing intervals, the Product could significantly reduce triglycerides (TG) levels and have hypolipidemic effects on the liver, providing a promising clinical development value.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 2 May 2025

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.*